Survivin: An inhibitor of apoptosis in pediatric cancer
Pediatric Blood & Cancer2006Vol. 47(1), pp. 4–13
Citations Over Time
Abstract
Abstract Survivin is an inhibitor of apoptosis protein (IAP) expressed in a large number of adult malignancies. Its expression levels correlate with more aggressive disease and poor clinical outcome in many of these tumors. As its expression is restricted in normal adult differentiated tissues, it has become of great interest as both a tumor prognostic marker and as a potential biologic target for future anti‐cancer therapies. Survivin expression and Survivin‐based therapies have been examined in many of the more common pediatric malignancies. We present an overview of Survivin function and current research exploring its biologic and therapeutic roles in pediatric tumors. Pediatr Blood Cancer © 2006 Wiley‐Liss, Inc.
Related Papers
- → Survivin: A Bifunctional Inhibitor of Apoptosis Protein(2004)185 cited
- → On the discovery of a potential survivin inhibitor combining computational tools and cytotoxicity studies(2019)14 cited
- → Survivin-Dependent and -Independent Pathways and the Induction of Cancer Cell Death by Tetra-O-methyl Nordihydroguaiaretic Acid(2006)26 cited
- Advances in research on Survivin ,the inhibitor of apoptosis in cancer diagnosis and therapy(2003)
- → Αποπτωτικοί και αντιαποπτωτικοί βιοδείκτες παιδιατρικών και ενήλικων ασθενών με σήψη ή SIRS(2023)